.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Citi
McKesson
Cerilliant
Argus Health
AstraZeneca
Medtronic
McKinsey
Daiichi Sankyo
QuintilesIMS

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Myocardial perfusion imaging methods and compositions
Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A.sub.2A adenosine receptor agonist to a human undergoing myocardial imaging as well as pharmaceutical compositions comprising at least one A.sub.2a receptor agonist, at least one liquid carrier, and at least one co-solvent.
Inventor(s): Belardinelli; Luiz (Palo Alto, CA), Rosner; Mitchell (Mountain View, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/533,025
Patent Claims: 1. A pharmaceutical composition comprising: a) about 400 .mu.g of a compound which has the formula: ##STR00020## b) at least one liquid carrier selected from the group consisting of water, saline, a buffer, and combinations thereof, c) at least one sodium phosphate buffer; d) EDTA; and e) propylene glycol in an amount of about 15% (w:v), wherein the pH of said pharmaceutical composition is from about 6 to about 8.

2. The pharmaceutical composition of claim 1, wherein the pH of said pharmaceutical composition is about 7.

3. The pharmaceutical composition of claim 1, wherein at least one liquid carrier is water.

4. The pharmaceutical composition of claim 3, wherein the water is distilled water or de-ionized water.

5. The pharmaceutical composition of claim 3 comprising 15% (w:v) propylene glycol and 100 mM phosphate buffer at pH 7 with 0.1% EDTA.

6. The pharmaceutical composition of claim 1, wherein the at least one sodium phosphate buffer is of a concentration of about 100 mM.

7. The pharmaceutical composition of claim 1 comprising 15% (w:v) propylene glycol and 100 mM phosphate buffer at pH 7 with 0.1% EDTA.

8. A kit comprising a vessel and the pharmaceutical composition of claim 1, wherein the pharmaceutical composition is contained within the vessel, and wherein the vessel is formed from either type I glass or plastic.

9. The kit of claim 8, wherein the vessel is formed from plastic.

10. A kit comprising a vessel and the pharmaceutical composition of claim 3, wherein the pharmaceutical composition is contained within the vessel, and wherein the vessel is formed from either type I glass or plastic.

11. The kit of claim 10, wherein the vessel is formed from plastic.

12. A method of producing coronary vasodilation comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 1 to a human in need thereof.

13. A method of producing coronary vasodilation comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 3 to a human in need thereof.

14. A method of myocardial perfusion imaging of a human in need thereof comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 1 and a radionuclide, wherein the myocardium is examined for areas of insufficient blood flow following administration the pharmaceutical composition and the radionuclide.

15. The method of claim 14, wherein the pharmaceutical composition and the radionuclide are administered separately.

16. The method of claim 14, wherein the pharmaceutical composition and the radionuclide are administered simultaneously.

17. The method of claim 14, wherein administration of the pharmaceutical composition causes at least a 2.5 fold increase in coronary blood flow for less than about 5 minutes.

18. The method of claim 14, wherein administration of the pharmaceutical composition causes at least a 2.5 fold increase in coronary blood flow for less than about 3 minutes.

19. A method of myocardial perfusion imaging of a human in need thereof comprising administering by intravenous (iv) bolus the pharmaceutical composition of claim 3 and a radionuclide, wherein the myocardium is examined for areas of insufficient blood flow following administration the pharmaceutical composition and the radionuclide.

20. The method of claim 19, wherein the pharmaceutical composition and the radionuclide are administered separately.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
McKesson
Teva
Baxter
Chubb
McKinsey
Merck
Daiichi Sankyo
Novartis
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot